Pfizer nabs fast OK for a new frontline lung cancer drug as pharma giant shows off its new R&D strategy

Pfizer CEO Ian Read got a little help from the FDA today in highlighting his recent pledge to rely on the late-stage pipeline for future revenue growth. The agency has stamped its approval on dacomitinib, a kinase inhibitor now headed for frontline duty against non-small cell lung cancer.